Fagron - oktober

1. [verwijderd] 31 oktober 2016 19:56

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   omaneus schreef op 31 oktober 2016 18:34:

   [...]ik heb het zeker al onderbouwd. Het sentiment zit nu ook niet mee gezien de olieprijs onderhandelingen.
   
   Daarom verwacht ik dus nu geen 9 euro maar 8 euro
   

   Niet overdrijven.
2. [verwijderd] 31 oktober 2016 20:11

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   JacobusJW schreef op 31 oktober 2016 19:56:

   [...]
   
   "Archief, historische posities...." downloaden.
   Linksonder op "current positions" klikken.
   Daarna bovenin op driehoekje "full issuer name" en Fagron kiezen.
   

   dan zie je de actuele short.
3. Machiavelli 31 oktober 2016 20:13

   auteur info

   • Machiavelli

     Lid sinds: 10 okt 2016

     Laatste bezoek: 18 mrt 2025

   • Aanbevelingen

     Ontvangen: 1273

     Gegeven: 2957

   •    Aantal posts: 2.987

   shortsell.nl/short/Fagron
   
   Link werkt niet...Fagron
   4,23% short
4. Azoia 31 oktober 2016 23:03

   auteur info

   • Azoia

     Lid sinds: 12 sep 2016

     Laatste bezoek: 12 jul 2024

   • Aanbevelingen

     Ontvangen: 16

     Gegeven: 61

   •    Aantal posts: 201

   FTSE slips, though posts fifth straight month of gains
   share with twitter share with LinkedIn share with facebook share via e-mail
   0
   10/31/2016 | 05:57pm CET
   A red London bus passes the Stock Exchange in London
   Britain's top share index retreated on Monday but posted a fifth straight month of gains, as advertising group WPP rose after reporting its third-quarter results.
   The blue chip FTSE 100 <.FTSE> index was down 0.6 percent at 6,954.22 points by the close, but up 0.8 percent for October.
   
   Shares in WPP (>> WPP PLC) rose 4 percent and posted their biggest daily gain in four months. WPP, the world's largest advertising group, reported results in line with expectations.
   
   "We are encouraged by the positive nature of this morning’s update and remain fundamentally positive on WPP’s ability to capitalise on a solid medium-term outlook for global advertising spend," Roddy Davidson, an analyst at Shore Capital Markets, said in a note.
   
   However, investors were less optimistic about some forthcoming earnings. The top fallers were Shire (>> Shire PLC), which reports results on Tuesday, and Next (>> NEXT plc), whose results are due on Wednesday, down 2.8 percent and 3.2 percent respectively.
   
   The FTSE 100 index posted a fifth month of gains in a row for the first time since early 2013. The index has been buoyed by a rally in banks and mining companies.
   
   Banks were boosted by last week's well-received earnings from Barclays (>> Barclays PLC) and Lloyds (>> Lloyds Banking Group PLC), with the FTSE 350 banking sector <.FTNMX8350> hitting its highest level for the year.
   
   October saw the FTSE 100 set a record high of 7,129.83 points. A weaker pound has bolstered the index, which has rallied about 10 percent since Britain voted in June to leave the European Union. The cheaper pound helps the index's international, dollar-earning firms.
   
   Some analysts, however, were more cautious on the outlook for British shares.
   
   "(The FTSE) is still continuing the positive run of gains since Brexit, so it's a Brexit bounce. But it's run into that previous record high ... and pulled back quite significantly from there," said Jasper Lawler, market analyst at CMC Markets.
   
   Investors, he added, were holding back before upcoming central bank interest rate decisions and the U.S. presidential election on Nov. 8.
   
   "I think no one's really got the confidence to buy the market up through into new record highs."
   
   The more domestically exposed FTSE 250 index <.FTMC> fell 0.6 percent, and was down 1.8 percent for the month of October. It has been weighed down by a spate of profit warnings and big declines from companies including Berendsen (>> Berendsen PLC), Cobham (>> Cobham plc), Senior (>> Senior plc) and Keller (>> Keller Group plc).
   
   (Editing by Mark Heinrich)
5. Azoia 31 oktober 2016 23:04

   auteur info

   • Azoia

     Lid sinds: 12 sep 2016

     Laatste bezoek: 12 jul 2024

   • Aanbevelingen

     Ontvangen: 16

     Gegeven: 61

   •    Aantal posts: 201

   Canada drugmaker Cipher mulls sale - sources
   share with twitter share with LinkedIn share with facebook share via e-mail
   0
   10/31/2016 | 08:25pm CET
   Cipher Pharmaceuticals Inc (>> Cipher Pharmaceuticals Inc), a Canadian specialty pharmaceuticals manufacturer, has hired an investment bank to review strategic alternatives, including a potential sale, people familiar with the matter said.
   Cipher Pharmaceuticals Inc (>> Cipher Pharmaceuticals Inc), a Canadian specialty pharmaceuticals manufacturer, has hired an investment bank to review strategic alternatives, including a potential sale, people familiar with the matter said.
   
   The strategic review comes amid increased U.S. scrutiny of specialty drug prices, which has weighed on the valuations of many Canadian specialty pharmaceutical companies with U.S. revenues.
   
   There is no certainty that a sale of Cipher will occur, the people cautioned, asking not to be identified because the deliberations are confidential.
   
   Shares of Cipher shot up as much as 22 percent after the Reuters report. They were up 8.3 percent on Monday afternoon in Toronto.
   
   "The company is working with an advisor to consider various strategic alternatives potentially available to enhance shareholder value, with a focus on the U.S. business," Cipher said in a press statement following the report.
   
   Toronto, Ontario-based Cipher, which has a market capitalization of $89.5 million, specializes in treatments for skin disorders. Its products include Nuvail, a topical film that treats fragile nails, and Bionect, which treats skin irritations. It has about $35 million in debt, according to regulatory filings.
   
   Cipher shares have dropped more than 70 percent from 2015 highs amid a broader pullback in the specialty pharmaceutical sector that has also impacted shares of Valeant Pharmaceuticals International Inc (>> Valeant Pharmaceuticals Intl Inc) and Concordia International Corp (>> Concordia International Corp).
   
   Concordia explored strategic alternatives earlier this year, before opting to improve liquidity by raising debt. Valeant has said it plans to sell about $8 billion in assets to help pay down its $30 billion debt pile.
   
   Cipher has been in the spotlight since its largest shareholder, John Mull, in July published a letter calling for the company's board to consider trimming its size, replacing some members of the management team and reviewing its business model. He did not call on the company to sell itself.
   
   In August, the board reconstituted itself, with four board members stepping down and three joining. Last month, Mull, who owns nearly 40 percent of the company, was appointed chair of the board of directors and Stephen Lemieux took over from Norman Evans as chief financial officer.
   
   Last year, Cipher acquired dermatology company Innocutis Holdings LLC for $45 million. In May, it bought the rights to a tattoo removal cream from Dalhousie University in Nova Scotia.
   
   (Reporting by Carl O'Donnell in New York and John Tilak in Toronto; Editing by Meredith Mazzilli, Bernard Orr)
   
   By Carl O'Donnell and John Tilak
   
6. Azoia 31 oktober 2016 23:05

   auteur info

   • Azoia

     Lid sinds: 12 sep 2016

     Laatste bezoek: 12 jul 2024

   • Aanbevelingen

     Ontvangen: 16

     Gegeven: 61

   •    Aantal posts: 201

   Valeant Pharmaceuticals Intl : Shares Down on Bloomberg Report of Criminal Probe of Accounting
   share with twitter share with LinkedIn share with facebook share via e-mail
   0
   10/31/2016 | 09:09pm CET
   Federal prosecutors are looking into possible accounting-fraud charges against Valeant Pharmaceuticals International Inc. (>> Valeant Pharmaceuticals Intl Inc), Bloomberg News reported Monday, citing people familiar with the matter.
   
   Charges are possible within weeks, but no charging decisions have been made, Bloomberg reported.
   
   Valeant told Bloomberg "we are in frequent contact and continue to cooperate" with authorities.
   
   Valeant shares recently traded down 8.5% to $18.62.
   
   Full story at www.bloomberg.com/news/articles/2016-...
   
   Write to nymonitoring@dowjones.com
7. Machiavelli 1 november 2016 09:00

   auteur info

   • Machiavelli

     Lid sinds: 10 okt 2016

     Laatste bezoek: 18 mrt 2025

   • Aanbevelingen

     Ontvangen: 1273

     Gegeven: 2957

   •    Aantal posts: 2.987

   www.iex.nl/Forum/Topic/1339580/Fagron...
8. Beursgoeroe 1 november 2016 10:18

   auteur info

   • Beursgoeroe

     Lid sinds: 09 apr 2002

     Laatste bezoek: 17 sep 2023

   • Aanbevelingen

     Ontvangen: 2055

     Gegeven: 2

   •    Aantal posts: 7.975

   quote:

   JacobusJW schreef op 31 oktober 2016 19:56:

   [...]
   Niet overdrijven.
   

   koersdoel is toch € 15,00 ? ...
9. [verwijderd] 1 november 2016 17:55

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   JacobusJW schreef op 31 oktober 2016 19:51:

   [...]
   De Belgische FSMA heeft vandaag de shortposities weereens niet bijgewerkt.
   

   De Belgische FSMA heeft vandaag de shortposities weereens niet bijgewerkt.
   
   De stand per afgelopen donderdag is 1,79% oftewel ca 1,3 miljoen aandelen.
10. [verwijderd] 1 november 2016 18:32

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    1 2 3 schreef op 1 november 2016 10:18:

    [...]
    
    koersdoel is toch € 15,00 ? ...
    

    De koersdoelen liggen tussen 8€ en 15€.
    
12. [verwijderd] 2 november 2016 08:56

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Dat kan dus betekenen dat de Shorters er erg langzaam (of niet) uit gaan. Wees dus op je hoede! Daarnaast daalt mijn inziens de koers omdat het momentum even weg is. Komt wel weer terug!
    
13. [verwijderd] 2 november 2016 18:07

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    De shortposities zijn tot en met maandag ongewijzigd. Het blijft bij 1,79%.
    
    Nu maar hopen dat Clinton verliest want dat komt de biotech ten goede.
    En dan....dan moeten ZE met spoed minimaal 1,3 miljoen aandelen coveren.;-)